RxMapper Secures $5.7 Million SAFE Round

Scottsdale, Arizona, June 21, 2024 – RxMapper, a DNA-guided personalized medication platform and telehealth consult practice, announced today it has successfully raised $5.7 million in a SAFE funding round. This investment will further propel RxMapper's mission to transform healthcare by leveraging the power of genomics to identify medications that are likely to be safe and effective based on the patient's DNA, while flagging those that should be avoided.

"RxMapper's mission is to utilize genomic insights to provide the best possible care for every patient," said Jim Miller, President and Co-Founder of RxMapper. "Our patient-centric approach not only reduces healthcare costs but, most importantly, improves the health and well-being of our patients. For those struggling to find the right medication for their debilitating condition, RxMapper is a new lease on life."

RxMapper's scalable platform is designed to serve populations of all sizes, but RxMapper has chosen to focus on serving small to medium-sized companies with 50 to 5,000 employees through a trusted network of brokers, consultants, and transparent PBMs. Miller emphasized, "This funding will accelerate RxMapper's growth, allowing us to serve an ever-increasing number of companies that prioritize the health, happiness, and productivity of their employees."

About RxMapper
RxMapper is a DNA-guided personalized medication platform and telehealth consult practice. RxMapper sequences and analyzes a patient's DNA and identifies medications that are likely safe and effective for them, while flagging those that should be avoided. This highly personal, DNA-guided approach to medication selection and management leads to improved health outcomes and reduced healthcare costs for both patients and employers.